The Relationship of Breast Cancer Subtypes with the Event of Metastasis in Dr. M. Djamil Hospital Padang

Ahmad Fakhrozi Helmi¹, Daan Khambri², Rony Rustam²

¹ Student of the Education Program for Specialist in Surgery, Faculty of Medicine, Andalas University, Padang, Indonesia
² Department of Surgery, Division of Surgical Oncology, Faculty of Medicine, Andalas University/ Dr. M. Djamil General Hospital, Padang, Indonesia

ARTICLE INFO

Keywords:
Breast Cancer
Molecular Subtype
Metastasis

*Corresponding author:
Ahmad Fakhrozi Helmi

E-mail address:
ahmadfakhrozihelmi@gmail.com

All authors have reviewed and approved the final version of the manuscript.

https://doi.org/10.32539/bsm.v5i4.410

ABSTRACT

Background: One of the high mortality rates from breast cancer is related to the incidence of metastases. It is known that >90% of deaths in breast cancer are related to the incidence of metastases and the complications that follow. Breast cancer is divided into several subtypes based on the expression of receptor genes in breast cancer tissue, namely Luminal A, Luminal B, HER2 and Triple Negative Breast Cancer (TNBC). This study aims to determine the relationship between breast cancer subtypes and the incidence of metastases in Dr. M. Djamil Padang. Methods: This study used a retrospective case-control study to breast cancer patients with metastatic at Dr M Djamil Hospital, Padang from 2016-2021. The research subjects were 260 breast cancer patients who met the inclusion criteria. The study subjects were divided into 130 patients as the case group with metastases and 130 patients as the control group with no metastases. To determine the relationship between breast cancer subtypes and the incidence of metastases, the chi-square test was used. If the p value <0.05, it can be concluded that it is significant. Furthermore, analysis is continued to obtain an odds ratio (OR) in identifying risk opportunities with Cochran's and Mantel-Haenszel statistics common odds ratio estimate. The data were analysed using the Statistical Package for Social Sciences (SPSS) program. Result: Characteristics of the subjects in this study can be seen that there is a relationship between hormonal contraception, T and N status with the incidence of metastasis (p <0.05). Patients with metastases were more common with breast cancer subtypes luminal B (61.5%), HER2+ (21.5%), TNBC (14.6%) and luminal A (2.3%). The most common locations for breast cancer metastases were lung (48.5%), bone (26.2%), liver (19.2%), brain (5.4%) and other places (0.8%). There was a relationship between breast cancer subtypes and the incidence of metastasis (p<0.038). The highest risk of metastases was in patients with TNBC subtype with OR = 7.74 (95% CI 1.72-34.79). There was no relationship between breast cancer subtypes with metastatic location (p>0.05) and breast cancer subtypes TNBC had a risk (OR) of 9.60 (95% CI 1.96-47.14) times increasing the risk of metastases in brain. Conclusion: It can be concluded that there was a relationship between breast cancer subtypes and the incidence of metastasis.

1. Introduction

Breast cancer is the most common type of cancer found worldwide, and is the fifth most common cause of cancer death among all types of cancer. Based on data from Globocan 2020, it is estimated that there are 2,261,419 million new cases (11.7% of all cancer cases in the world) each year beating lung cancer (11.4%), colorectal (10.0%), prostate (7.3%), and stomach (5.6%), with 684,996 (6.9%) of them ending in death.¹ In Indonesia, based on data obtained from the Dharmais Cancer Hospital in 2018, breast cancer is the most common type of cancer with a prevalence of 19.18%, and is 34.30% among all cancer incidences in women.²

One of the high mortality rates from breast cancer is related to the incidence of metastases. It is known that >90% of deaths in breast cancer are related to the incidence of metastases and the complications that follow.³

Breast cancer is divided into several subtypes based on the expression of receptor genes in breast cancer...
tissue, namely Luminal A (Estrogen Receptor positive and/or Progesterone receptor positive, Human Epidermal Growth Factor Receptor 2 negative, and Ki-67 14%), Luminal B (Estrogen Receptor positive). Receptor positive and/or Progesterone positive, Human Epidermal Growth Factor Receptor 2 negative, and Ki-67>14% or Estrogen Receptor positive and/or Progesterone positive, Human Epidermal Growth Factor Receptor 2 positive), Human Epidermal Growth Factor Receptor 2 Positive (Estrogen Receptor negative, Progesterone negative, Human Epidermal Growth Factor Receptor 2 positive), and Basal Like or often known as Triple Negative Breast Cancer (TNBC) (Estrogen Receptor negative, Progesterone negative, Human Epidermal Growth Factor Receptor 2 negative).4

Breast cancer is known as a cancer with high heterogeneity, both in terms of the molecular characteristics that form the basis for the division of breast cancer subtypes, or tumour characteristics, biologic behaviour and clinicopathology such as lymphovascular infiltration, and their response to various therapeutic modalities to prognosis.5,6 Molecular subtypes also correlate with the risk of local and regional recurrence or distant metastasis of breast cancer.7

Although there have been several studies examining the relationship between breast cancer subtypes and metastasis, these studies are still very limited with inconsistent and very mixed results. Based on this background description, a study was conducted to determine whether there was a relationship between breast cancer subtypes with the event of metastasis in Dr. M. Djamil Hospital Padang.

2. Methods

This study used a retrospective case-control study to breast cancer patients with metastatic at Dr M Djamil Hospital, Padang from 2016-2021.

The research subjects were 260 breast cancer patients who met the inclusion criteria. The study subjects were divided into 130 patients as the case group with metastases and 130 patients as the control group with no metastases.

To determine the relationship between breast cancer subtypes and the incidence of metastases, the chi-square test was used. If the p value <0.05, it can be concluded that it is significant. Furthermore, analysis is continued to obtain an odds ratio (OR) in identifying risk opportunities with Cochran’s and Mantle-Haenszel statistics common odds ratio estimate. The data were analysed using the Statistical Package for Social Sciences (SPSS) program.

3. Result

In this study, it was found that there was a relationship between a history of hormonal contraception, T and N status with the incidence of metastasis (p<0.05). However, there was no relationship between age, marital status, menopausal status, breastfeeding history, grade, ER, PR, HER2 and Ki67 with the incidence of metastasis (p>0.05). (Table 1)

Table 2 shows that patients with metastases are more common with breast cancer subtypes luminal B (61.5%), HER2+ (21.5%), TNBC (14.6%) and luminal A (2.3%). Meanwhile, in patients who did not have metastases, the subtypes of breast cancer were luminal B (60.0%), HER2+ (24.6%), luminal A (8.5%) and TNBC (6.9%). Table 5.3 shows that the most common locations for breast cancer metastases are lung (48.5%), bone (26.2%), liver (19.2%), brain (5.4%) and other places (0.8%).
Table 1 Subject characteristics

| Characteristic                  | Category          | Group           | p-value |
|---------------------------------|-------------------|-----------------|---------|
|                                 |                   | Case (f/%) | Control (f/%) |         |
| Ages                            | < 50 years        | 52 (40,0)    | 55 (42,3)    | 0,801   |
|                                 | ≥ 50 years        | 78 (60,0)    | 75 (57,7)    |         |
| Marriage                        | Not married       | 4 (3,1)      | 0 (0)        | 0,122   |
|                                 | Married           | 126 (96,6)   | 130 (100,0)  |         |
| Menopause                       | Yes               | 55 (42,3)    | 67 (51,5)    | 0,172   |
|                                 | No                | 75 (57,7)    | 63 (48,5)    |         |
| Hormonal Contraception         | Yes               | 108 (83,1)   | 83 (63,8)    | 0,001*  |
|                                 | No                | 22 (16,9)    | 47 (36,2)    |         |
| Breast Feeding                 | Yes               | 124 (95,4)   | 125 (96,2)   | 1,000   |
|                                 | No                | 6 (4,6)      | 5 (3,8)      |         |
| Grade                          | I                 | 3 (2,3)      | 7 (5,4)      | 0,219   |
|                                 | II                | 106 (81,5)   | 109 (83,8)   |         |
|                                 | III               | 21 (16,2)    | 14 (10,8)    |         |
| T Status                       | T1                | 0 (0)        | 4 (1,5)      | <0,001* |
|                                 | T2                | 4 (3,1)      | 22 (16,9)    |         |
|                                 | T3                | 26 (20,0)    | 55 (42,3)    |         |
|                                 | T4                | 100 (76,9)   | 49 (37,7)    |         |
| N Status                       | N0                | 3 (2,3)      | 36 (27,7)    | <0,001* |
|                                 | N1                | 57 (43,3)    | 69 (53,1)    |         |
|                                 | N2                | 50 (38,5)    | 20 (15,4)    |         |
|                                 | N3                | 20 (15,4)    | 5 (3,8)      |         |
| ER                             | Positive          | 66 (50,8)    | 78 (60,0)    | 0,170   |
|                                 | Negative          | 64 (49,2)    | 52 (40,0)    |         |
| PR                             | Positive          | 63 (48,5)    | 75 (57,7)    | 0,172   |
|                                 | Negative          | 67 (51,5)    | 55 (42,3)    |         |
| HER2                           | Positive          | 60 (46,2)    | 64 (49,2)    | 0,710   |
|                                 | Negative          | 70 (53,8)    | 66 (50,8)    |         |
| KI67                           | >20 %             | 127 (97,7)   | 119 (91,5)   | 0,054   |
|                                 | <20 %             | 3 (2,3)      | 11 (8,5)     |         |

*p<0.05 significant

Table 2. Breast cancer subtypes

| Subtype        | Group           | Total |
|----------------|-----------------|-------|
|                | Case (f/%)      | Control (f/%) |         |
| Luminal A      | 3 (2,3)         | 11 (8,5)     | 14 (5,4) |
| Luminal B      | 80 (61,5)       | 78 (60,0)    | 158 (60,8) |
| HER2+          | 28 (21,5)       | 32 (24,6)    | 60 (23,1) |
| TNBC           | 19 (14,6)       | 9 (6,9)      | 28 (10,8) |
| **Total**      | 130 (100,0)     | 130 (100,0)  | 260 (100,0) |

Table 3. Locations of breast cancer metastases

| Metastasis    | F  | %  |
|---------------|----|----|
| Bone          | 34 | 26,2 |
| Brain         | 7  | 5,4 |
| Lung          | 63 | 48,5 |
| Liver         | 25 | 19,2 |
| Others        | 1  | 0,8 |
Table 4 shows that there is a relationship between subtypes of breast cancer and the incidence of metastases (p<0.05). The highest chance of metastatic risk was in patients with TNBC subtype with OR = 7.74 (95% CI 1.72-34.79) followed by luminal B with OR = 3.76 (95% CI 1.01-13.99).

| Subtype | Group | Case (f/%) | Control (f/%) | Total (f/%) | p-value | OR (95% CI) |
|---------|-------|------------|---------------|-------------|---------|-------------|
| Luminal A | | 3 (2,3) | 11 (8,5) | 14 (5,4) | 0,038* | 1,01 (0,03-0,58) |
| Luminal B | | 80 (61,5) | 78 (60,0) | 158 (60,8) | 3,76 (1,01-13,99) * | |
| HER2+ | | 28 (21,5) | 32 (24,6) | 60 (23,1) | 3,21 (0,81-12,67) | |
| TNBC | | 19 (14,6) | 9 (6,9) | 28 (10,8) | 7,74 (1,72-34,79) * | |

Table 5 shows that there is no relationship between breast cancer subtypes and the location of metastases (p>0.05). The risk for breast cancer subtypes based on each metastatic location can be seen in table 6.

| Subtype | Metastasis | Bone (f/%) | Brain (f/%) | Lung (f/%) | Liver (f/%) | Other (f/%) | Total (f/%) | p-value |
|---------|------------|------------|-------------|------------|-------------|-------------|-------------|---------|
| Luminal A | | 1 (2,9) | 0 (0) | 1 (1,6) | 1 (4,0) | 0 (0) | 3 (2,3) | 0,196 |
| Luminal B | | 24 (70,6) | 2 (28,6) | 36 (57,1) | 17 (68,0) | 1 (100,0) | 80 (61,5) | |
| HER+ | | 6 (17,6) | 1 (14,3) | 18 (28,6) | 3 (12,0) | 0 | 28 (21,5) | |
| TNBC | | 3 (8,8) | 4 (57,1) | 8 (12,7) | 4 (16,0) | 0 | 19 (14,6) | |

Table 6. Risk for breast cancer subtypes based on each metastatic site

| Subtype | Metastasis | Bone | Brain | Lung | Liver | OR (95% CI) |
|---------|------------|------|-------|------|-------|-------------|
| Luminal A | | 0,70 (0,06-7,99) | n/a | 1,91 (0,17-21,57) | 0,47 (0,04-5,35) |
| Luminal B | | 1,74 (0,74-3,97) | 4,33 (0,81-23,26) | 1,44 (0,71-2,92) | 0,71 (0,28-1,78) |
| HER+ | | 1,39 (0,51-3,78) | 1,69 (0,19-14,63) | 0,44 (0,18-1,04) | 2,29 (0,63-8,30) |
| TNBC | | 2,07 (0,56-7,59) | **9,60 (1,96-47,14)** * | 1,35 (0,51-3,61) | 0,88 (0,26-2,91) |

Table 6 shows that the TNBC breast cancer subtype has a risk (OR) of 9.60 (95% CI 1.96-47.14) times increasing the risk of brain metastases.

4. Discussion

In this study, the risk factors for the use of hormonal contraception were associated with the incidence of metastases in breast cancer (p = 0.001). This was also stated by Jamnasi (2016) where 17% of patients with metastatic breast cancer had a history of using hormonal family planning. Hormonal family planning has been known as a risk factor for breast cancer. Research by Hasnita et al (2019) explains that the use of hormonal family planning is the most dominant hormonal risk factor in the incidence of breast cancer. The use of hormonal birth control containing estrogen and progesterone will cause a proliferative effect on the ductal epithelium of the breast and if followed by loss of control in apoptosis, it will result in continuous tissue proliferation without being able to be controlled.8,9,10

Tumor size is a predictor to see the survival rate of
breast cancer patients. Research conducted by Laura S et al (2005) showed that there was a relationship between breast cancer tumor size and lymph node metastasis and infiltration. The same thing was also shown in this study where T status in breast cancer patients was associated with the incidence of metastases, which means that the higher the T value, the higher the probability of metastases (p < 0.001). This is in line with the results of research by Anwar et al (2020) which explains that infiltration into the skin and chest wall (T4a-c) has a higher risk for distant metastases. Something that could explain the relationship between tumor size and the risk of metastases is that as cancer cells progress, cancer cells accumulate a specific set of genetic events to have the ability to spread to regional lymph nodes and distant organs.11,12,13,14

In this study, N status was found to be associated with the incidence of metastases in breast cancer (p < 0.001). This study is in line with the results of the Jamnasi (2016) study which found a positive N status associated with metastasis in the case group. This was also found by other studies such as Anwar et al (2020), who found positive axillary lymph nodes (N1-3) to have a higher risk of distant metastases.8,13

In this study, it was found that in the case group, the subtypes of breast cancer were luminal B (61.5%), HER2+ (21.5%), TNBC (14.6%) and luminal A (2.3%). Meanwhile, in the control group, breast cancer subtypes were luminal B (60.0%), HER2+ (24.6%), luminal A (8.5%) and TNBC (6.9%). The luminal B subtype is a subtype with positive hormonal receptors, Her 2 positive/negative and Ki-67 > 20. The number of metastases in Luminal B compared to Luminal A is related to the amount of Ki 67 expression.15

In this study, the most common locations for breast cancer metastases were lung (48.5%), bone (26.2%), liver (19.2%), brain (5.4%) and the ovaries (0.8%). This is in accordance with a study by Anwar et al (2020) which showed the lungs were the most common site (12.7%), followed by bone (12.3%), pleura (8.8%), liver (5.5%), and brain (1.9%) but different results were obtained by Xiao et all (2018) namely bone (3.28%), followed by lungs (1.52%), liver (1, 20%), and brain metastases (0.35%).13, 16, 17

This study found that there was a relationship between specific breast cancer subtypes and the incidence of metastasis (p<0.05). This result is reinforced by the results of another study by Xiao et al (2016) which showed the same results. Breast cancer subtype as we know is one of the determining factors in metastatic organotropism in breast cancer.17,18

This study explains that the highest risk of metastases is in patients with TNBC subtype with OR = 7.74 (95% CI 1.72-34.79) followed by luminal B with OR = 3.76 (95% CI 1, 01-13.99). This result is also in accordance with what was stated by Anwar (2020) that the TNBC subtype has the highest rate of distant metastases (27.3%). Triple negative is a subtype of breast cancer with ER, PR, and HER-2 negative. This subtype has the worst prognosis compared to other subtype classifications. The triple negative subtype has high invasiveness, high potential for metastasis and recurrence, and poor prognosis.19,20

In this study, there was no relationship between breast cancer subtypes and the location of metastases (p>0.05). TNBC had a risk (OR) of 9.60 (95% CI 1.96-47.14) times increasing the risk of brain metastases. These results are consistent with those described by Xiao (2018) for TNBC subtypes having a higher chance of risk in brain (OR, 1.95), liver (OR, 1.35), and lung (OR, 1.34) metastases.) but the rate of bone metastases was significantly lower (OR, 0.64).17

We are trying to investigate whether there is an association between breast cancer subtypes and the incidence of metastases that will be useful for the management of these patients. However, this study has some limitations related to the retrospective case-control design based solely on secondary data. Analysis of disease duration, treatment effect, and comorbid contribution was also not possible. Larger studies involving multiple centre or population-based studies with longer periods are needed to confirm this study.

5. Conclusion

In this study, it was proven that there was a relationship between breast cancer subtypes and the incidence of metastasis and TNBC Subtype had a risk...
9.60 times increasing the risk of brain metastases.

6. References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Ca Cancer J Clin. 2021; 71: 209-49

2. Kemenkes RI. Infodatin. Beban Kanker di Indonesia. Kementerian Kesehatan Republik Indonesia. 2019: 1-16

3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394-424.

4. Firdaus VRP, Asri A, Khambri A, Harahap WA. Hubungan Grading Histopatologi dan Infiltrasi Limfovaskular dengan Subtipe Molekuler pada Kanker Payudara Invasif di Bagian Bedah RSUP. Dr. M. Djamil Padang. JKA. 2016; 5(1): 165-72

5. Turkoz FP, Solak M, Petekkaya I, Keskin O, Kertmen N, Srici F, et al. Association between common risk factors and molecular subtypes in breast cancer patients. The Breast. 2013; 22: 344-50

6. Soediro R, Nugroho RS, Gondhowiardjo SA, Djoerdan Z, Poetiray EDC. Karakteristik Subtipe Kanker Payudara Berdasarkan Status Hormonal dan Her-2. Journal of the Indonesian Radiation Oncology Society. 2010; 1(2): 43-7

7. Chen XS, Ma CD, Wu JY, et al. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer. Tumori 2010; 96 (1): 103-110

8. Jamnasi et al. Faktor resiko terjadinya metastasis jauh pada kanker payudara. Radiologi dan Onkologi Indonesia, 2016; 55-59

9. Hasnita et al. Pengaruh faktor risiko hormonal pada pasien kanker payudara di RSUP.DR.M.Djamal padang. Jurnal kesehatan andalas, 2019; 8(3).

10. Morch et al. Contemporary hormonal contraception and the risk of breast cancer. The new England Journal medicine. 2017; 377(1): 2228-3.

11. Elkin et al. The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999. Cancer. 2005; 104(6): 1149-57. Https://doi.org/10.1002/cncr.21285.

12. Laura et al. Tumour size as a predictor of axillary node metastases in patients with breast cancer. Anz j surg. 2006; 76(11): 1002-6. Https://doi.org/10.1111/j.1445-2197.2006.03918.x

13. Anwar et al. Risk factors of distant metastasis after surgery among different breast cancer subtypes: a hospital-based study in Indonesia. World journal of surgical oncology. 2020; 18: 117 [https://doi.org/10.1186/s12957-020-01893-w]

14. Qiu et al. A multiple breast cancer stem cell model to predict recurrence of t1-3, n0 breast cancer. BMC cancer. 2019; 19: 729. Https://doi.org/10.1186/s12885-019-5941-5.

15. Yuan et al, Ki-67 expression in luminal type breast cancer and its association with the clinicopathology of the cancer, Oncology letter, 2016; 2101-2105

16. Perhimpunan Ahli Bedah Onkologi Indonesia. Panduan Penatalaksanaan Kanker 2020. II. (Djoko H, Haryono S, Arief HW, eds.). PERABOI (Perhimpunan Ahli Bedah Onkologi Indonesia); 2020.

17. Wu, Q. et al. Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study. Oncotarget 8, 2017; 27990-27996.

18. Wenjing Chen1, Andrew D. Hoffmann. Organotropism: new insights into molecular mechanisms of breast cancer metastasis. Precision Oncology. 2018.

19. Szymiczek A, Lone A, Akbari MR. Molecular
intrinsic versus clinical subtyping in breast cancer: A comprehensive review. Clin Genet. 2021; 99(5): 613–37.

20. Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020; 22(1): 1–13.